Clinical Trial Update: Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a phase 1/2 study evaluating Brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• B-precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• Brexucabtagene Autoleucel (brexucabtagene autoleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED